Transforming the future use of injectable medicines outside the hospital: Increasing capacity in the NHS

无菌复方是一个实践已经改变的领域，因为出现了更复杂、更个性化的药物。对无菌配药的需求不断增加，临床团队每天都要依靠日益复杂的化合物进行治疗。这一繁荣伙伴关系旨在创建一个平台，将改变英国和全球未来注射药物的使用。我们最终设想，无论是在社区还是在医院，通过自动化过程生产的一系列重新配方的可注射药物，无论是在社区还是在医院，都可以大幅减少在任何适当的环境下提供这些药物所需的医疗资源需求。这可能需要在英格兰围绕具有高度标准化的轴辐式模式对配药服务进行大规模重组，并适应/采用自动化的新方法，以便更有效地利用药房/配药和改变注射药物使用的护理劳动力中的资源。支持这些药物相互关联的交付是对延长保质期(稳定性)、管理简单、生产量、供应链和降低成本的持续推动。我们的项目专注于这些点的联系，将药物配方、制造和分销视为一个完整的系统，其中复合过程的元素可以跨不同的地点发生，具有不同的可扩展性和最优化，取决于使用/要求和保质期/配方和无菌制造设施的要求的复杂性。这包括在高度监管的高变异药品生产领域实施机器人制造和人工智能。

Aseptic compounding is an area where practice has been transformed by the emergence of more complex, personalised medicines. The demands on aseptic dispensing are continually increasing, with clinical teams relying on increasingly complex compounds for treatments given every single day.This Prosperity Partnership aims to create a platform that will transform the future use of injectable medicines in the UK and globally. We envisage, ultimately, a range of reformulated injectable medicines suited to the setting in which they are administered, whether in the community or a hospital, manufactured through an automated process dramatically reducing the demand placed on healthcare resource required to deliver them in whatever setting is appropriate. This potentially requires a wholesale reconfiguration of compounding service in England around a hub and spoke model with high degrees of standardisation and the adaption/adoption of new approaches to automation making more efficient use of resources both in pharmacy/compounding and in the nursing workforce transforming the use of injectable medicines. Underpinning the interlinked delivery of these medicines is a continual drive for extended shelf-lives (stability), simplicity in administration, volume of manufacture, supply chain and cost reduction.Our project focusses on the nexus of these points, considering medicine formulation, manufacture and distribution as a whole system, where elements of the compounding process can occur across different sites, with different scalability and optimisation depending on both use/requirement and shelf-life/complexity of formulation and aseptic manufacturing facility requirements. This incorporates implementing robotics manufacturing and AI into the heavily regulated area of high variation medicines production.